Last reviewed: June 16, 2026
Last updated: June 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
The GLP-1 story spans nearly three decades, beginning with a hormone discovery in 1984 and evolving into one of medicine's most impactful weight loss tools. By 2023, GLP-1 medications had helped millions manage weight and metabolic health, though access remained uneven until compounding pharmacies expanded availability. PlexusDx now delivers these innovations to all 50 states at transparent, fixed monthly prices.
GLP-1 Hormone Discovery and Early Research (1984–1999)
Glucagon-like peptide-1, or GLP-1, was first identified in 1984 as a hormone produced by intestinal cells called L-cells. Researchers noticed that GLP-1 stimulated insulin release only when blood sugar was elevated, offering a unique mechanism for managing glucose without causing dangerous low blood sugar episodes. This natural brake system fascinated endocrinologists who saw therapeutic potential in a hormone that worked safely with the body's own regulation.
Throughout the 1990s, scientists studied how GLP-1 also slowed gastric emptying and signaled satiety to the brain—effects independent of its insulin action. Clinical teams recognized that synthetic versions of GLP-1 could address multiple metabolic problems simultaneously: blood sugar control, reduced appetite, and slower digestion. These early trials established the scientific foundation that would eventually lead to weight loss medications.
The First GLP-1 Medications Enter the Market (2005–2010)
Exenatide (Byetta), a synthetic GLP-1 agonist derived from Gila monster saliva, became the first injectable GLP-1 medication approved by the FDA in 2005. It was marketed exclusively for type 2 diabetes and required twice-daily injections, limiting adoption among patients seeking convenience. Physicians observed that patients on exenatide frequently lost weight as a secondary benefit, sparking interest in GLP-1 for obesity management.
Liraglutide (Victoza) followed in 2009 as a once-daily injectable option with improved tolerability. A higher-dose formulation called Saxenda was later approved specifically for chronic weight management in 2014, but insurance restrictions and high out-of-pocket costs kept it out of reach for many patients seeking weight loss support. These early approvals proved the therapeutic principle but highlighted access barriers that would persist for years.
Semaglutide's Launch: The Turning Point (2017–2021)
Novo Nordisk introduced semaglutide (Ozempic) in 2017 for type 2 diabetes with once-weekly dosing, a major convenience advantage over prior GLP-1 agents. The weekly injection schedule meant patients could maintain steady hormone levels with simpler regimens, improving real-world adherence. Social media and word-of-mouth eventually amplified reports of dramatic weight loss in both diabetic and non-diabetic users, creating public demand far exceeding original marketing.
Semaglutide (Wegovy) received FDA approval specifically for chronic weight management in June 2021, legitimizing GLP-1 as a dedicated obesity treatment. Clinical trials showed that patients taking semaglutide lost approximately 15% of their body weight on average—substantially more than older GLP-1 medications or lifestyle interventions alone. This evidence, combined with celebrity endorsements and media coverage, sparked a global shortage and made access a critical healthcare equity issue.
Modern Access Through Compounding: PlexusDx's Role Today
Starting in 2022–2023, licensed 503A compounding pharmacies began manufacturing semaglutide and tirzepatide, expanding access beyond FDA-approved branded versions facing supply constraints and insurance gatekeeping. Compounded medications offer identical active ingredients at significantly lower costs, with no insurance requirement, membership fees, or prior authorization delays. PlexusDx sources all compounded GLP-1 injections from licensed 503A facilities and provides semaglutide starting at $149/month with flat pricing—meaning dose increases do not raise monthly cost.
The Precision Peptide Genetic Test available through PlexusDx identifies individual genetic variants (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313) that influence peptide-pathway sensitivity and metabolic response. This personalization layer allows clinicians to optimize which GLP-1 compound—semaglutide, tirzepatide, or dual-compound formulas—may work best for each patient's genetic profile. HSA/FSA eligibility and all-50-states availability represent a democratization of a treatment class once reserved for wealthy or insured populations.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
When did GLP-1 medications become available for weight loss, not just diabetes?
Liraglutide (Saxenda) was approved for chronic weight management in 2014, but semaglutide (Wegovy) in June 2021 marked the turning point—offering weekly dosing and superior weight loss outcomes that transformed public awareness. Compounded semaglutide through PlexusDx became widely accessible in 2023, eliminating insurance barriers and cost obstacles.
What clinical evidence supports GLP-1 for weight loss?
Semaglutide trials showed mean weight loss of 15% of body weight, with some patients exceeding 20% loss. Tirzepatide (a dual GIP/GLP-1 agonist) showed even greater reductions, around 22%, in the SURMOUNT clinical program. PlexusDx offers both compounds with transparent $149–$289/month pricing, allowing patients to access these evidence-based treatments without insurance.
How much does GLP-1 medication cost at PlexusDx?
Compounded Semaglutide Injection starts at $149/month and remains flat regardless of dose increases—the price never goes up when your dose does. Oral Semaglutide starts at $249/month, and dual-compound formulas (GLP-Squared) start at $249/month for injection. All are HSA/FSA eligible, with no membership fee or insurance requirement across all 50 states.
Are compounded GLP-1 medications from PlexusDx safe?
Yes. PlexusDx sources all compounded medications exclusively from licensed 503A compounding pharmacies, meeting strict regulatory standards for purity, potency, and sterility. The active ingredients are identical to FDA-approved versions; the primary difference is lower cost and broader access. Common side effects (nausea, constipation) mirror branded GLP-1s and typically diminish over time.
How does the Precision Peptide Genetic Test help me choose the right GLP-1?
The Precision Peptide test ($99 add-on) analyzes 14 metabolic pathways and 150+ genetic insights, identifying your variants in GLP1R, GIPR, FTO, and MC4R that influence how your body responds to GLP-1 compounds. Patients with stronger GIPR variants may benefit more from tirzepatide; others respond optimally to semaglutide alone. This personalization optimizes treatment selection and improves outcomes.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Your Journey: How to Reduce Wegovy Dose Safely and Effectively
Semaglutide and Probiotics: What You Need to Know for Your Weight Loss Journey